Santa Ana Bio Raises $168M in Combined Series A and B to Advance Precision Medicines
A California-based precision immunology company, Santa Ana Bio, Inc., has emerged from stealth with a combined series A and B funding of $168 to deliver precision medicines for patients struggling with inflammatory diseases.
According to the company’s announcement, it raised $43 million in a Series A funding round led by Versant Ventures and $125 in a Series B funding round led by GV (Google Ventures).
Found... moreSanta Ana Bio Raises $168M in Combined Series A and B to Advance Precision Medicines
A California-based precision immunology company, Santa Ana Bio, Inc., has emerged from stealth with a combined series A and B funding of $168 to deliver precision medicines for patients struggling with inflammatory diseases.
According to the company’s announcement, it raised $43 million in a Series A funding round led by Versant Ventures and $125 in a Series B funding round led by GV (Google Ventures).
Founded in 2022 by Peter Emtage Ph.D., and Danny Wells PhD, the startup’s funding rounds included the participation of all existing investors and new investors, Access Biotechnology and a Silicon Valley-based venture capital firm, Andreessen Horowitz (a16z) Bio + Health and RTW.
Read more: https://nextdigitalhealth.com/funding-news/santa-ana-bio-raises-168m-inseries-a-and-b-funding-to-advance-precision-medicines-for-inflammatory-illneses/
#fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #HealthcareFunding #Biotechnology #PrecisionMedicine #nextdigitalhealth #Wi4 #vineetagrawal
